Lundbeck Secures EU Orphan Status for Cushing’s Syndrome Candidate

Endogenous Cushing's syndrome, often driven by excess adrenocorticotropic hormone (ACTH), forces the body into a state of chronic cortisol overproduction. This hormonal imbalance leads to severe metabolic, cardiovascular, and neuropsychiatric complications. While surgery remains the primary intervention, many patients face limited options when surgery is not feasible or fails to provide sustained remission, leaving a clear gap in standard medical care.

Asedebart functions by specifically binding to ACTH, blocking its interaction with the melanocortin 2 receptor in the adrenal glands. By inhibiting this signaling pathway, the drug aims to suppress the overproduction of steroids, including cortisol and mineralocorticoids. Lundbeck is currently evaluating the candidate’s safety and efficacy in ongoing proof-of-concept trials for Cushing's disease and congenital adrenal hyperplasia.

"Orphan designation in the European Union is an important recognition of both the unmet need in Cushing's and the scientific rationale behind asedebart," said Johan Luthman, Executive Vice President of R&D at Lundbeck. The designation provides the company with regulatory incentives, such as protocol assistance and fee reductions, alongside a potential ten-year market exclusivity period upon approval. The drug has already garnered similar regulatory momentum in the United States and Japan, reinforcing its status as a key asset in Lundbeck’s expanding neuro-rare disease pipeline.